D. E. Shaw & Co., Inc. Madrigal Pharmaceuticals, Inc. Put Options Transaction History

D. E. Shaw & Co., Inc.

10 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2024 Aug 14, 2024	SELL	$193.33 - $291.99 $1.59 Million - $2.39 Million	-8,200 Reduced 90.11%	900 $252,000
Q1 2024 May 15, 2024	BUY	$171.37 - $283.23 $1.56 Million - $2.58 Million	9,100 New	9,100 $2.43 Million
Q2 2021 Aug 16, 2021	BUY	$97.2 - $137.59 $602,640 - $853,058	6,200 Added 163.16%	10,000 $974,000
Q1 2021 May 17, 2021	BUY	$108.54 - $125.2 $412,452 - $475,760	3,800 New	3,800 $444,000
Q1 2020 May 15, 2020	SELL	$66.76 - $93.49 $667,600 - $934,900	-10,000 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$84.28 - $118.5 $842,800 - $1.19 Million	-10,000 Reduced 50.0%	10,000 $911,000
Q3 2019 Nov 14, 2019	SELL	$84.4 - $106.53 $844,000 - $1.07 Million	-10,000 Reduced 33.33%	20,000 $1.72 Million
Q2 2019 Aug 14, 2019	BUY	$91.13 - $142.5 $838,396 - $1.31 Million	9,200 Added 44.23%	30,000 $3.14 Million
Q1 2019 May 15, 2019	BUY	$103.48 - $143.84 $1.03 Million - $1.44 Million	10,000 Added 92.59%	20,800 $2.61 Million
Q4 2018 Feb 14, 2019	BUY	$94.77 - $215.54 $1.02 Million - $2.33 Million	10,800 New	10,800 $1.22 Million

299

22M

757K

370K

Ticker MDGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,103,400
Market Cap $3.56B
Description
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.